Literature DB >> 2420011

Immunobiology of human gliomas.

D E Bullard, G Y Gillespie, M S Mahaley, D D Bigner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2420011

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  13 in total

Review 1.  Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Authors:  Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

Review 2.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

3.  Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes.

Authors:  C D Rice; N G Baldwin; R T Biron; H D Bear; R E Merchant
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

Review 4.  Current challenges in designing GBM trials for immunotherapy.

Authors:  Shiao-Pei Weathers; Mark R Gilbert
Journal:  J Neurooncol       Date:  2015-01-11       Impact factor: 4.130

Review 5.  Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations.

Authors:  R E Merchant; M D Ellison; H F Young
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

6.  The mononuclear cell infiltrate compared with survival in high-grade astrocytomas.

Authors:  M L Rossi; N R Jones; E Candy; J A Nicoll; J S Compton; J T Hughes; M M Esiri; T H Moss; F F Cruz-Sanchez; H B Coakham
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

7.  Human neuroblastoma cell growth in xenogeneic hosts: comparison of T cell-deficient and NK-deficient hosts, and subcutaneous or intravenous injection routes.

Authors:  W J Turner; J Chatten; L A Lampson
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

8.  MTH-68/H oncolytic viral treatment in human high-grade gliomas.

Authors:  L K Csatary; G Gosztonyi; J Szeberenyi; Z Fabian; V Liszka; B Bodey; C M Csatary
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

9.  Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family.

Authors:  R J Boado; W M Pardridge; H V Vinters; K L Black
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

Review 10.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.